|
Thursday, November 07
|
| Session Title |
Speaker(s) |
|
8:00 AM - 11:45 AM
|
International Food Allergy Symposium – Morning Program
International Food Allergy Symposium requires separate registration fee. Admission by ticket only.
Supported by an independent educational grant from DBV Technologies
Moderators: David R. Stukus, MD, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI
Prevention
Multiple countries now have recommendations for early allergenic solid food introduction to help prevent food allergy. However, these guidelines differ on what, when and how to introduce, providing conflicting information. Moreover, there are other emerging factors, beyond solid food introduction, which are not incorporated in the present guidelines but may be relevant to the prevention of food allergy. This session will review the evidence to date, discuss guideline discrepancies and present data on the horizon that goes beyond the present guidelines toward where the next breakthroughs may be, to educate attendees about where we stand in our ability to comprehensively help prevent food allergy development.
8:00 am
Welcome and Introductions
David R. Stukus, MD, FACAAI
Matthew Greenhawt, MD, MSc, MBA, FACAAI
8:05 am – Luisa Businco Memorial Lecture
Harmonization, Differences in Guidelines, Unmet Needs and Implementation Barriers
Jonathan Hourihane, MD
8:35 am
The Microbiome and Exposome: A Saucerful of Secrets
Susan Prescott, MD, PhD
9:05 am
The Role of Diet Diversity and Other Factors Beyond Early Introduction in Promoting Prevention
Carina Venter, PhD, RD
9:45 am
Refreshment Break
Assessing Prevalence
Methodologies in how to measure food allergy prevalence differ tremendously among westernized countries. Birth, infant and population-level cohorts are invaluable tools for the study of food allergy across a nationally-representative population, in particular to assess the prevalence of food allergy through the use of oral food challenges. However, the U.S. continues to lack such an approach. This session will detail how food allergy prevalence has been assessed using food challenge in three large international cohorts.
10:00 am
Welcome and Introductions
David R. Stukus, MD, FACAAI
Matthew Greenhawt, MD, MSc, MBA, FACAAI
10:05 am
Rectifying Direct and Indirect Methods of Assessing Prevalence: Where We Are, Why Rates Differ and the Importance of Population-level Studies
Rachel Peters, MD, MPH, PhD
10:35 am
Birth and Infant Cohorts: Why These Are Needed – the International Perspective
Syed Hasan Arshad, MBBS, DM
11:05 am
Food Allergy in Africa: the SAFAR Cohort
Michael Levin, MBChB, MMed, PhD, FACAAI |
|
Moderator:
David R. Stukus, MD, FACAAI
Moderator:
Matthew Greenhawt, MD, MSc, MBA, FACAAI
Speaker:
Jonathan Hourihane, MD
Speaker:
Susan Prescott, MD, PhD
Speaker:
Carina Venter, PhD, RD
Speaker:
Rachel Peters, MPH, PhD
Speaker:
Syed H. Arshad, MBBS, DM
Speaker:
Michael Levin, MD, PhD, FACAAI
|
|
11:45 AM - 12:50 PM
|
International Food Allergy Symposium – Luncheon
International Food Allergy Symposium requires separate registration fee. Admission by ticket only.
Supported by an independent educational grant from DBV Technologies
From the Horse’s Mouth – The FDA Perspective on Treatment and Unmet Needs
This lunchtime discussion will address regulatory aspects of food allergy that impact our patients on a daily basis.
Moderator: Warner W. Carr, MD, FACAAI
12:00 pm
An Update on Thresholds and Labeling
Stefano Luccioli, MD, FDA Center for Food Safety and Applied Nutrition, Office of Compliance |
|
Moderator:
Warner W. Carr, MD, FACAAI
Speaker:
Stefano Luccioli, MD
|
|
1:00 PM - 4:45 PM
|
International Food Allergy Symposium – Afternoon Session
International Food Allergy Symposium requires separate registration fee. Admission by ticket only.
Supported by an independent educational grant from DBV Technologies
Moderators: David R. Stukus, MD, FACAAI and Matthew Greenhawt, MD, MSc, MBA, FACAAI
Treatment
There is a bright horizon for food allergy treatment, with commercial options for peanut allergy anticipated in the next year. Moreover, new approaches are under investigation in the clinical pipeline to help foster evolution in the treatment approach. It is important for parents and providers to understand what treatment options exist and how to communicate them and foster shared decision-making among patients regarding these options.
1:00 pm
Welcome and Introductions
David R. Stukus, MD, FACAAI
Matthew Greenhawt, MD, MSc, MBA, FACAAI
1:05 pm
Treatment Updates: What Are Our Present Options?
Edwin H. Kim, MD, MS, FACAAI
1:35 pm
New Horizons: Anticipating the Next Evolution in Treatments
Rima A. Rachid, MD
2:05 pm
Shared Decision-making and Understanding Parental Preference in Choice of Food Allergy Treatment
Matthew Greenhawt, MD, MSc, MBA, FACAAI
2:45 pm
Refreshment Break
Bigger Success Begets Bigger Problems: Issues on the Horizon
With the development of new treatment options, there have been similar innovations made regarding new diagnostic testing to complement older, more established methods. Understanding the relative value, utility and costs associated with these approaches is imperative. Equally important is shaping the conversations with parents and patients, so that providers can anticipate and understand the information that patients are receiving outside of our scope of practice. This session will address these issues that are impacting current and future approaches to management.
3:00 pm
Welcome and Introductions
David R. Stukus, MD, FACAAI
Matthew Greenhawt, MD, MSc, MBA, FACAAI
3:05 pm
Cost-effective Practices in Food Allergy and Anaphylaxis
Marcus Shaker, MD, FACAAI
3:35 pm
Something Borrowed, Something Blue, Something Old, Something New: Making Sense of Older Versus New Diagnostic and Lab Technologies for Treatment Monitoring
Wayne G. Shreffler, MD, PhD
4:05 pm
Social Media, Advocacy and the Rise of Myths and Alternative Facts in Food Allergy
David R. Stukus, MD, FACAAI |
|
Moderator:
David R. Stukus, MD, FACAAI
Moderator:
Matthew Greenhawt, MD, MSc, MBA, FACAAI
Speaker:
Edwin H. Kim, MD, FACAAI
Speaker:
Rima A. Rachid, MD
Speaker:
Matthew Greenhawt, MD, MSc, MBA, FACAAI
Speaker:
Marcus Shaker, MD, MSc, FACAAI
Speaker:
Wayne G. Shreffler, MD, PhD
Speaker:
David R. Stukus, MD, FACAAI
|
|
5:00 PM - 6:00 PM
|
International Food Allergy Symposium – Texas Pro-Con Thunderdome (With Refreshments!)
International Food Allergy Symposium requires separate registration fee. Admission by ticket only.
Supported by an independent educational grant from DBV Technologies
Refreshments will be provided.
Not For Credit
Two allergists enter...one leaves. See leading experts in the field debate some of the hottest topics facing the field at present, Texas-style. This session will include three pro/con debates surrounding interesting and controversial topics related to food allergy immunotherapy. With beer! (This session is non-CME.)
Moderators: David R. Stukus, MD, FACAAI and Matthew Greenhawt, MD, MSc, MBA, FACAAI
5:00 pm
Welcome and Introductions
David R. Stukus, MD, FACAAI
Matthew Greenhawt, MD, MSc, MBA, FACAAI
5:05 pm
We Need Further Development of FDA-approved OIT Approaches
Anna Nowak-Wegrzyn, MD, FACAAI
Richard L. Wasserman, MD, PhD, FACAAI
5:25 pm
EPIT Versus OIT for Treating Peanut Allergy
David M. Fleischer, MD, FACAAI
Brian P. Vickery, MD
5:45 pm
OFC's Are Necessary for Starting Food Allergy Treatment
Aikaterini (Katherine) Anagnostou, MD, MSc, PhD, FACAAI
Douglas Mack, MD, MSc
|
|
Moderator:
David R. Stukus, MD, FACAAI
Moderator:
Matthew Greenhawt, MD, MSc, MBA, FACAAI
Speaker:
Anna Halina Nowak-Wegrzyn, MD
Speaker:
Richard L. Wasserman, MD, PhD, FACAAI
Speaker:
David M. Fleischer, MD, FACAAI
Speaker:
Brian P. Vickery, MD
Speaker:
Aikaterini (Katherine) Anagnostou, MD, PhD, FACAAI
Speaker:
Douglas Mack, MD, MSc
|
|
6:30 PM - 8:30 PM
|
Non-CME Corporate Forum: A Presentation Sponsored by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Not For Credit
Presented by:
Jonathan Corren, MD
Ellen Sher, MD
Please join Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. for a Non-CME Forum presentation at the ACAAI Conference. Located at the Marriott Marquis Houston. Food and beverage to be served.
Also, visit Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. at Booth #313. |
|
|
Non-CME Corporate Forum: Using Shared Decision-making to Discuss Treatment Options and Identify Appropriate Patients for Oral Immunotherapy, and a Review on Practical Implementation Experience
Supported by Aimmune Therapeutics
Not For Credit
Presented by:
Joel M. Hartman, MD
Jennifer Jobrack, Principal, The Food Allergy Pros, LLC
Douglas T. Johnston, DO
Bruce Joshua Lanser, MD
Increasing awareness of the challenges of living with food allergies by walking through a patient journey is key in understanding the patient and caregiver’s perspective. Shared decision making is a discussion tool that can be leveraged to help identify appropriate patients for peanut oral immunotherapy and to make treatment decisions that best align with what is most important to patients/ caregivers; including the patient’s/caregiver’s willingness, support-system, goals, values, and perspective. In addition, our faculty will close with sharing practical experiences in implementing oral immunotherapy.
Also, visit Aimmune Therapeutics at Booth #619. |
|
|
